Organon & Co. reported third quarter 2025 non-GAAP adjusted net income of $263 million, or $1.01 per diluted share, compared to $226 million, or $0.87 per diluted share, in the third quarter of 2024. Non-GAAP adjusted EBITDA margin rose to 32.3% from 29.0% year over year, primarily due to a 14% reduction in non-GAAP operating expenses. Full year 2025 revenue guidance was revised to $6.2 billion to $6.25 billion, down from the previous range of $6.3 billion to $6.4 billion. Nominal revenue growth is now expected between -3.2% and -2.4%. As of September 30, 2025, cash and cash equivalents totaled $672 million, and debt stood at $8.8 billion. The Board of Directors declared a quarterly dividend of $0.02 per share, payable December 11, 2025.